Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, double-blind, randomized, placebo-controlled study of Cyclobenzaprine (TNX-102 SL) to evaluate the efficacy in patients with Post-traumatic-stress-disorders who have experienced civilian traumas and those with military-related traumas

Trial Profile

A Phase III, double-blind, randomized, placebo-controlled study of Cyclobenzaprine (TNX-102 SL) to evaluate the efficacy in patients with Post-traumatic-stress-disorders who have experienced civilian traumas and those with military-related traumas

Planning
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms RECOVERY
  • Sponsors Tonix Pharmaceuticals Holding Corp
  • Most Recent Events

    • 11 Dec 2018 According to a Tonix Pharmaceuticals media release, the company has closed its previously announced underwritten public offering.The Company expects to use the net proceeds from this offering to help fund this new phase 3 trial using a modified trial design for its lead product candidate, Tonmya and for working capital and other general corporate purposes.
    • 29 Nov 2018 According to a Tonix Pharmaceuticals Holding Corp media release, the company plans to start this trial in the first quarter of 2019 and expect to have topline data in the first half of 2020.
    • 12 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top